The University of Texas System

Other

Dnatrix, Inc.

Tyrell Corporation

Moleculin, LLC

Lumatherm, Inc.

Charles A Conrad

Timothy Madden

Waldemar Priebe

Izabela Fokt

Stanislaw Skora

Candelaria Gomez-Manzano

Marcin Cybulski

Frederick Lang, Jr

Slawomir Szymanski

W K Alfred Yung

Juan Fueyo-Margareto

Frank Tufaro

Juan Fueyo

Amy Heimberger

Wk Alfred Yung

Robert Alan Conrad

Arkadiusz Kazimierski

Jeffrey N Myers

Waldeman Priebe

Hong Jiang

Robert Conrad

David Earl Massey

Carl Joseph Glim

Thomas Ray Ingersoll

Manoj G Perera

Leposava Antonovic

Liwei Guo

Tomothy Madden

Candeleria Manzano-Gomez

Fred Lang

Stainslaw Skora

Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.

Esters of 2-deoxy-monosaccharides with anti proliferative activity

Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy.

Adenovirus and immunomodulator combination therapy

The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.

Biomarkers and combination therapies using oncolytic virus and immunomodulation

Provided herein are compounds which intercalate into the DNA of a cell and are capable of crossing the blood brain barrier of a formula provided herein. Pharmaceutical compositions of the compounds and methods of treating cancer, for example brain, lung, or pancreatic cancer, are also provided herein.

DNA binding agents with a minor groove binding tail

Esters of 2-deoxy-monosacharides with anti proliferative activity

The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.

Oncolytic adenovirus armed with therapeutic genes

Provided herein are methods of treating brain tumors by administering a therapeutically effective amount of a compound of the Formulas I or II to a patient in need thereof.

Inhibitors of glycolysis useful in the treatment of brain tumors

Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.

Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs)

Novel compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are provided herein.

Acetates of 2-deoxy monosaccharides with anticancer activity

The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.

Orally bioavailable caffeic acid related anticancer drugs

Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS)

Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%.

Methods of treating skin disorders with caffeic acid analogs

Growing community of inventors

Houston, TX, United States of America

Charles A Conrad